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gates the rate of OOP in Korea. METHODS: Data from
World Health Report 2002 are used to analyze the rela-
tion between per capita total health care expenditure
(THE) of GDP and rates of OOP or rates of prepaid (i.e.
tax, premium, etc). To explain why the rate of OOP is
high in Korea, we compare price elasticity in demand for
medical services between countries from previous studies.
To argue that the OOP rate is not so serious currently and
in the future, we show the trend of OOP rates in Korea
for three decades. RESULTS: By comparing the relation
between per capita THE of GDP and rates of OOP or
rates of prepaid, we found the fact that the amount of
THE of GDP or THE of GDP per capita would be same
regardless of either high or low OOP rates, or high rates
of OOP might spend less THE because it can prevent
“moral hazard” in using medical services. This fact is
support by the higher price elasticity in demand for
medical services in Korea. In addition, we found that
OOP rates came down from 85% (1970) to 41% (2000)
out of THE in Korea and they have rapidly decreased due
to the expansion of health care insurance and other
factors. CONCLUSIONS: This shows that the OOP rate
in Korea is not severe as worried. Rather, high rates 
of prepaid could spend more in THE. We also argue 
that adequate levels of OOP rates in health insurance
systems could prevent unnecessary use of medical 
services, which follow to cost containment in THE.
However, this could be a barrier to accessing medical care
services for people on low incomes. Further studies on the
trade-offs between the levels of “barriers” and “moral
hazard” are suggested.
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OBJECTIVE: There is increasing concern that children
with special health care needs may face restricted access
to care due to potentially inadequate reimbursement to
health plans and providers caring for them. We employed
data from a State’s Medicaid, Title V and Title XXI pro-
grams to analyze the implications of different reimburse-
ment strategies. METHODS: Enrollment and claims data
for 188,556 children with at least 6 (aged 1–19) or 3
(newborns) months continuous enrollment during 1999
were employed. Children were grouped into mutually
exclusive Clinical Risk Group (CRG) categories (such as
healthy, malignancies and catastrophic). Reimbursement
models considered include demographics-adjusted capita-
tion, health-status adjusted capitation, carve-outs and
reinsurance for children with annual charges above a
threshold. RESULTS: Premium estimates from demo-
graphics-adjusted capitation model showed little varia-
tion across CRG categories within each program ($133
PMPM for healthy and $170 PMPM for moderate/dom-
inant chronic in the Title XXI program) resulting in
proﬁts on healthy ($42 PMPM) and losses on chronic
CRG categories (for example a loss of $191 PMPM for
minor chronic). While results from health-status adjusted
capitation model indicated wide disparity in premium
estimates across CRG categories ($94 PMPM for healthy
and $695 PMPM for moderate/dominant chronic in 
the Title XXI program), there still was wide variation in
expenditures within each CRG category creating incen-
tives to risk select. Financial risks to health plans and
providers were reduced slightly in malignancies and 
catastrophic carved-out model. More pronounced reduc-
tions in ﬁnancial risk were provided by reinsurance.
CONCLUSIONS: This study shows that demographics-
adjusted capitation fails to account for diverse ﬁnancial
needs of children with chronic conditions. Health-status
adjusted capitation, on average, supports varying needs
of children with chronic conditions, but the likelihood of
risk selection remains. Reinsurance further reduces incen-
tives to risk select, but incentives to control health care
costs are lost once charges exceed the threshold.
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OBJECTIVE: State funded healthcare systems, such as
the UK, tend to be cautious with the diffusion of new
drugs for fear of ﬁnancial pressures. One way of con-
trolling diffusion, while maximising the beneﬁts for
patients, is to set up an outcome guarantee. This presen-
tation describes a case study using lipid lowering drugs,
recently completed. METHODS: The key stakeholders
were identiﬁed and each declared their interest on an
agreed matrix. This formed the basis of an outcome guar-
antee contract. Near patient testing and audit nurses were
used to identify at risk patients and enter them into an
agreed care pathway. Patients were given lifestyle advice,
re-tested and monitored every 3 months throughout the
18 months of the project. Results of treatment with lipid
lowering drugs were measured against their claimed 
beneﬁts and adjusted for concordance. If the drug under-
performed, according to agreed criteria, the pharmaceu-
tical company agreed to refund the cost of those drugs.
RESULTS: The concept was readily accepted by the
stakeholders. Two thousand at risk patients were identi-
ﬁed from 1 primary care trust, of which 1400 were eligi-
ble to enter the outcome guarantee. Six hundred patients
to date have completed the project. Final results are due
in July. Of those who have completed the project, the
majority have reached target level and no refund has been
due. A qualitative evaluation of the stakeholders is cur-
rently under way and will be reporting in August 2002.
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CONCLUSIONS: An outcome guarantee is an acceptable
way for a nationally funded health service to partner a
pharmaceutical company for optimal diffusion of drugs
likely to beneﬁt a patient population. The model has
potential for replication in other therapeutic areas and
other healthcare systems.
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OBJECTIVE: Outcomes in healthcare technology reviews
now increasingly include cost as well as effectiveness. The
aim of this study is to report the ﬁndings and implications
of a survey regarding the usefulness of NHS Economic
Evaluation Database (NHS EED) structured abstracts
within this process. METHODS: Postal survey of lead
authors of Technology Assessment Reviews (TARs) com-
missioned by the UK’s National Institute for Clinical
Excellence. The questionnaire investigated the usefulness
of NHS EED regarding: search strategy, data extraction,
quality assessment, and requirement for new modeling
studies. Qualitative data were requested, including opin-
ions regarding NHS EED. RESULTS: NHS EED was used
in 90% of all identiﬁed reviews (n = 46). The question-
naire response rate was 57%. The percentage of scores 3
or above, 2 or below, or N/A were, respectively: search
strategy = 60%, 22%, 17%; data extraction = 26%,
26%, 48%; quality assessment = 30%, 22%, 48%;
requirement for new modeling studies = 22%, 26%,
52%. The results were expanded upon in the qualitative
data from the respondents. CONCLUSIONS: Where
several economic evaluations had been published NHS
EED was utilized and valued as an independent source,
and was highly useful to non-economists. However, those
undertaking TARs also used conﬁdential data from
company submissions and cost data for studies not cri-
tiqued on NHS EED. More standardization and use of
quality checklists in reviews of economic studies is clearly
needed. The ﬁndings will help in developing and improv-
ing NHS EED in its role of providing health outcomes
and economic evidence in TARs.
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OBJECTIVE: To estimate the most costly disease condi-
tions affecting medical, absenteeism, and short term dis-
ability (STD) expenditures affecting a subset of American
employers. METHODS: The Medstat Group’s 1999
Health and Productivity Management (HPM) Database
was used for this analysis. The HPM database links
medical, pharmacy, STD, and absence claims for over
340,000 employees. Medstat’s Episode Grouping soft-
ware product was used to classify and organize employ-
ees’ inpatient, outpatient, emergency department (ED)
and pharmaceutical claims temporally, so they could 
be connected to the treatment of any given condition.
Absence and STD claims associated with each clinical
episode were then added. The most costly physical and
mental health conditions were then ranked by their
overall medical, pharmacy, absence and STD expendi-
tures. RESULTS: Across all physical health conditions,
employers paid an average of $2505 per eligible employee
for medical care (71% of total), $316 per employee for
STD (9% of total), and $703 per employee in absence
(20% of total). Medical care expenditures included
money for: inpatient care–$687 (20% of total), out-
patient care–$1321 (38% of total), ED treatment–$57
(2% of total), and pharmaceuticals–$440 (12% of total).
When considering per-eligible payments for mental health
conditions, $94 (53% of total) was paid through health
beneﬁts, $23 (13% of total) was paid through STD pro-
grams, and $61 (34% of total) was as a result of employee
absence from work. Medical expenditures for mental
health care included money for inpatient care–$21 (12%
of total), outpatient care–$45 (25% of total), ED treat-
ment–$0.3 (0.2% of total), and pharmaceuticals–$28
(15% of total). CONCLUSIONS: Although health care
expenditures account for the majority of costs faced by
American businesses, productivity-related costs can be
high as well. Inpatient, outpatient, ED, and drug cost,
along with STD and absence costs, varied greatly by
disease.
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OBJECTIVE: Falls are a major problem for the 
community-dwelling elderly. About 30% of this group
experience a fall each year and between 4 and 10% 
of community-dwelling elders experience a fall-related
injury. Further, falling occurrence is a signiﬁcant predic-
tor of institutionalization and death. The objective of this
study was to provide an annual estimate of the direct
medical costs associated with fall-related injuries among
the community dwelling elderly. The study was done from
the payer’s perspective. METHODS: Data from the 1997
Medical Expenditure Panel Survey (MEPS) were analyzed
to identify elderly respondents who reported a fall-related
